EU sees 2025 pharma export uptick amid competitiveness concerns

New figures debuted by the European Union (EU) person uncovered a important emergence successful the year-on-year worth of pharma commercialized seen crossed the portion successful 2025 – stats the EU says correspond a grounds commercialized equilibrium for its medicines sector.

In 2025, the worth of EU cause exports totalled €366.2bn ($429.3bn), marking a 16% emergence from the €315.7bn the pharma commercialized crossed the national brought successful during 2024.

While exports took an uptick, the EU full cause import walk was besides 21% higher successful 2025, with countries crossed the governmental national forking retired €145.7bn for medicines passim the year.

This leaves the EU with a 2025 commercialized surplus of €220.5bn successful 2025, astir €30bn larger than the €195.3bn surplus successful 2024.

According to Eoin Ryan, pharma managing expert for Europe astatine GlobalData, the EU’s commercialized show is “impressive”, considering it occurred against the backdrop of geopolitical and economical uncertainty linked to US tariff policies.

When comparing the full worth of ex-Europe exports crossed nations successful the EU, Ireland took the helm implicit its peers – bringing successful conscionable implicit a 4th of the EU’s full pharma commercialized worth done its €93.8bn contribution. Meanwhile, Germany and Belgium took 2nd and 3rd place, and medicines exports from each state raked successful €67.9bn and €38.5bn, respectively, for the EU.

In 2025, the US was the main destination for EU cause exports, with 44% (or €160.6bn) of the union’s full medicines exports heading to the US market.

However, Ryan noted that these trends could beryllium a motion of “frontloading”, arsenic US importers looked to enactment 1 measurement up of tariff threats posed by the Trump administration. “There is already grounds that the EU-to-US medicines commercialized travel slowed successful Q1 2026 and is apt to beryllium confined to a weaker maturation outlook,” helium said.

15% tariffs placed connected the EU's branded cause imports to the US volition play a portion successful this trend, though nations without a woody volition soon beryllium taxable to 100% import taxes.

While commercialized bodies similar the European Federation of Pharmaceutical Industries and Associations (EFPIA) voiced their concerns connected the implications of the EU-US commercialized deal, experts antecedently interviewed by Pharmaceutical Technology accidental that Europe’s pharma commercialized with the US volition stay critical, contempt tariff turmoil impacting the union’s bottommost line.

The affirmative commercialized surplus figures posted by Eurostat travel arsenic the EU looks to boost the competitiveness of its pharma manufacture connected the planetary stage, arsenic the federation contends with heated rivalry from the US and China.